Can-Fite BioPharma announces new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer (527.00a, 0.00)
Can-Fite BioPharma provides an update on the regulatory status of its two lead drug candidates, Piclidenoson and Namodenoson (524.00a, +23.00)
Can-Fite BioPharma submits Phase 2 clinical study protocol to hospital in Italy for the first clinical evaluation of Piclidenoson in patients with Lowe syndrome (509.00a, -7.00)
Can-Fite BioPharma secures Australian patent allowance supporting namodenoson development and marketing in liver and pancreatic cancer (498.00a, 0.00)
Can-Fite BioPharma completes enrolment of the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis. (565.00a, -19.00)
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease (414.00a, +5.00)
Can-Fite secures Japanese patent allowance for Namodenoson's anti-obesity technology (449.00a, -11.00)
Can-Fite BioPharma reports positive clinical observation in Phase 2a pancreatic cancer study and highlights namodenoson's RAS signaling inhibition mechanism (463.00a, +3.00)
Can-Fite BioPharma announces peer-reviewed publication on piclidenoson for canine osteoarthritis in Frontiers in Veterinary Science study (543.00a, +24.00)
Can-Fite BioPharma upgraded to buy from hold at D. Boral Capital ($3.39, 0.00)
Powered by FactSet Research Systems Inc.